Article
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Acta neuropathologica - 1 Jul 2011
Capper David, Preusser Matthias, Habel Antje, Sahm Felix, Ackermann Ulrike, Schindler Genevieve, Pusch Stefan, Mechtersheimer Gunhild, Zentgraf Hanswalter, von Deimling Andreas
Abstract excerpt
Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) are frequent in benign and malignant human tumors and are emerging as an important biomarker. Over 95% of BRAF mutations are of the V600E type and specific small molecular inhibitors are currently under pre-clinical or clinical investigation. BRAF mutation status is determined by DNA-based methods, most...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.